Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01366391|
Recruitment Status : Unknown
Verified June 2011 by Biocinese.
Recruitment status was: Recruiting
First Posted : June 6, 2011
Last Update Posted : June 6, 2011
Metformin is one of the most commonly prescribed drugs worldwide for the treatment of Type 2 Diabetes. It has been currently used for the treatment of: polycystic ovary syndrome, gestational diabetes, metabolic syndrome and obesity. In patients with polycystic ovary syndrome (PCOS) the adverse side effects are a frequent cause for treatment discontinuation. In every day medical practice lower doses of Metformin are administered searching for the continuation of the treatment.
However, there is no clinical study to support this assertion. The objective of this study is to monitor and correlate the therapeutic effect of Metformin on patients with PCOS taking daily doses of 1500mg and 1000mg.
|Condition or disease||Intervention/treatment||Phase|
|Polycystic Ovary Syndrome||Drug: Metformin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||August 2011|
|Estimated Study Completion Date :||October 2011|
study parallel with one arm only.
Metformin 500 mg tablet (1000 or 1500 mg/day)
Other Name: Glifage 500 mg
- Plasma concentration of metformin [ Time Frame: First day after administration until 3 months after begining of treatment ]Blood samples are collected from each patient and the plasma concentration is analysed.
- Number of adverse events [ Time Frame: observation during 3 months of treatment ]All adverse events are registered during the treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01366391
|Contact: Naura Angonese, Dr||+55 45 2103 email@example.com|
|Contact: Josélia Manfio, Dr||+55 45 firstname.lastname@example.org|
|Toledo, Parana, Brazil, 85903-590|
|Contact: Joselia Manfio, Dr +55 45 2103 1907 email@example.com|
|Contact: Naura Angonese, Dr +55 45 2103 1900 firstname.lastname@example.org|
|Principal Investigator: Naura Angonese, Dr|
|Principal Investigator:||Naura Angonese, Dr||Biocinese|